Phase III FALCON study of bardoxolone in patients with autosomal dominant polycystic kidney disease is paused.- Reata Pharma
Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations The Company announced measures it… read more.